A community-based study proposed that an elevated FGF23 concentration is a subclinical marker of metabolic perturbations (diabetes, dyslipidemia, and obesity) in individuals with normal kidney function11. This evidence concerns the gene FGF23 and obesity due to melanocortin 4 receptor deficiency.